title: Branch retinal vein occlusion during fingolimod treatment in a patient with multiple sclerosis.
authors.forename: Roberto
authors.initials: R
authors.lastname: Gallego-Pinazo
authors.forename: Enrique
authors.initials: E
authors.lastname: España-Gregori
authors.forename: Bonaventura
authors.initials: B
authors.lastname: Casanova
authors.forename: Diamar
authors.initials: D
authors.lastname: Pardo-López
authors.forename: Manuel
authors.initials: M
authors.lastname: Díaz-Llopis
mesh_terms: D001766:Blindness / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D005260:Female; D000068876:Fingolimod Hydrochloride; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy*; D011409:Propylene Glycols / Q000009:adverse effects*; D012169:Retinal Vein / Q000187:drug effects / Q000473:pathology; D012170:Retinal Vein Occlusion / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D013110:Sphingosine / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine